Preemptive Lung Impedance-guided Therapy of Evolving Acute Heart Failure in Acute Myocardial Infarction Patients

Hillel Yaffe Medical Center

Status: Terminated

Conditions: Acute Heart Failure

Treatments: Other: Usual treatment of patients with developing acute heart failure; Device: Lung impedence-guided therapy

Study type: Interventional

Funder types: Other

Identifiers

NCT01264159

0090-10-HYMC

Details and patient eligibility

About

It is well known that 20-25% of patients hospitalized for acute myocardial infarction will develop acute heart failure during their hospitalization. Currently, the investigators have no reliable parameter for prediction of evolving acute heart failure in such a group of patients. As a result, the investigators have no way of preventing acute heart failure. Treatment of these patients only begins after appearance of clinical signs of acute heart failure. Lung impedance monitoring may be a good non-invasive parameter for prediction of evolving acute heart failure. This study will attempt to address whether preemptive lung impedence-guided therapy may prevent the development of overt acute heart failure and improve their clinical outcome.

Enrollment: 70 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients hospitalized in the ICCU for acute myocardial infarction and developing acute heart failure during their hospitalization

Exclusion criteria

• Patients with acute myocardial infarction with clinical and radiological signs of acute heart failure at admission

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

70 participants in 2 patient groups, including a placebo group

Control

Placebo Comparator group

Treatment:

Other: Usual treatment of patients with developing acute heart failure

Lung impedence-guided treatment

Active Comparator group

Treatment:

Device: Lung impedence-guided therapy